Paying attention to pharmacokinetic and pharmacodynamic mechanisms to progress in the area of anticholinergic use in geriatric patients

Current Drug Metabolism

Volumn 12, Issue 7, 2011, Pages 635-646

  De Leon, J ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Anticholinergic; Cholinergic antagonists; Muscarinic antagonists; Muscarinic receptors; Pharmacodynamics; Pharmacokinetics; Serum anticholinergic activity

Indexed keywords

BENZATROPINE; CARBAMAZEPINE; CHLORPHENIRAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CLOZAPINE; CYCLOBENZAPRINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DARIFENACIN; DILTIAZEM; DIPHENHYDRAMINE; DISOPYRAMIDE; ERYTHROMYCIN; FESOTERODINE; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; ITRACONAZOLE; KETOCONAZOLE; MUSCARINIC RECEPTOR; OXYBUTYNIN; PHENOBARBITAL; PHENYTOIN; PROMETHAZINE; QUETIAPINE; SOLIFENACIN; TOLTERODINE; UNINDEXED DRUG;

AGING; ANTICHOLINERGIC EFFECT; BIPOLAR DISORDER; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; CONSTIPATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; GENETIC VARIABILITY; GERIATRIC PATIENT; HUMAN; IN VITRO STUDY; RADIORECEPTOR ASSAY; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; XEROSTOMIA;

AGED; ATTENTION; CHOLINERGIC ANTAGONISTS; DRUG TOXICITY; GERIATRICS; HISTAMINE H2 ANTAGONISTS; HUMANS;

EID: 79961065476     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011796504518     Document Type: Review

References (142)

1. Olanow, C.W.; Stern, M.B.; Sethi, K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology, 2009, 72(21Supp 4), S1-S136.
2. Pirtosek, Z. 'Bad guys' among the antiparkinsonian drugs. Psychiatria Danubina, 2009, 21(1), 114-118.
3. Peters, N.L. Snipping the thread of life: antimuscarinic side effects of medications in the elderly. Arch. Intern. Med., 1989, 149(11), 2414-2420. (Pubitemid 19283196)
4. Abrams, P.; Andersson, K.E. Muscarinic receptor antagonists for overactive bladder. BJU Int., 2007, 100(5), 987-1006. (Pubitemid 47537675)
5. MacDiarmid, S.A. Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? BJU Int., 2007, 99(Suppl 3), 8-12. (Pubitemid 46608434)
6. Trifiro, G.; Spina, E. Age-related changes in pharmacodynamics. Curr. Drug Metabolism, 2011, in press.
7. DeVane, C.L.; Mintzer, J. Risperidone in the management of psychiatric and neurodegenerative disease in the elderly: an update. Psychopharmacol. Bull., 2003, 37, 116-132.
8. Cancelli, I.; Beltrame, M.; Gigli, G.L.; Valente, M. Drugs with anticholinergic properties: cognitive and neuropsychiatric sideeffects in elderly patients. Neurol. Sci., 2009; 30(2), 87-92.
9. Campbell, N.; Boustani, M.; Limbil, T.; Ott, C.; Fox, C.; Maidment, I.; Schubert, C.C.; Munger, S.; Fick, D.; Miller, D.; Gulati, R. The cognitive impact of anticholinergics: a clinical review. Clin. Interv. Aging, 2009, 4, 225-233.
10. Cantú, T.G.; Korek, J.S. Central nervous system reactions to histamine- 2 receptor blockers. Ann. Intern. Med., 1991, 114(12), 1027-1034.
11. Boustani, M.; Hall, K.S.; Lane, K.A.; Aljadhey, H.; Gao, S.; Unverzagt, F.; Murray, M.D.; Ogunniyi, A.; Hendrie, H. The association between cognition and histamine-2 receptor antagonists in African Americans. J. Am. Geriatr. Soc., 2007, 55(8), 1248-1253. (Pubitemid 47106699)
12. Smith, S.; Legros, J.J.; Le Mairo, M.; Rousseau, J.J.; Waucquez, J.L. Cimetidine neurotoxicity and anticholinergic activity (letter). Am. J. Psychiatry, 1982, 139(5), 704.
13. Tune, L.; Carr, S.; Hoag, E.; Cooper, T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am. J. Psychiatry, 1992, 149(10), 1393-1394.
14. Chew, M.L.; Mulsant, B.H.; Pollock, B.G.; Lehman, M.E.; Greenspan, A.; Mahmoud, R.A.; Kirshner, M.A.; Sorisio, D.A.; Bies, R.R.; Gharabawi, G. Anticholinergic activity of 107 medications commonly used by older adults. J. Am. Geriatr. Soc., 2008, 56(7), 1333-1341.
15. Gwee, M.C.; Cheah, L.S. Actions of cimetidine and ranitidine at some cholinergic sites: implications in toxicology and anesthesia. Life Sci., 1986, 39(5), 383-388. (Pubitemid 16070681)
16. Gwee, M.C.; Shoon, M.L.; Cheah, L.S. Dual action of ranitidine at cholinergic sites in the rat isolated anococcygeus muscle. J. Auton. Pharmacol., 1993, 13(3), 211-218. (Pubitemid 23163818)
17. Vyas, S.; Verma, S.C. The direct excitatory effects of cimetidine on the smooth muscle of guinea pig ileum. Agents Actions, 1981, 11(3), 193-195. (Pubitemid 11083771)
18. Petrovic, M.; Mariman, A.; Warie, H.; Afschrift, M.; Pevernagie, D. Is there a rationale for prescription of benzodiazepines in the elderly? Review of the literature. Acta Clinica Belgica, 2003, 58(1), 27-36. (Pubitemid 36396266)
19. Reynolds, D.S. The value of genetic and pharmacological approaches to understanding the complexities of GABA(A) receptor subtype functions: The anxiolytic effects of benzodiazepines. Pharmacol. Biochem. Behav., 2008, 90(1), 37-42.
20. Nordberg, A.; Wahlström, G. Cholinergic mechanisms in physical dependence on barbiturates, ethanol and benzodiazepines. J. Neural Transm., 1992, 88(3), 199-221.
21. Brown, J.H.; Taylor, P. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed.; L. L. Brunton; J. S. Lazo; K. L. Parker, Eds.; McGraw-Hill: New York, 2006; pp. 183-200.
22. Eglen, R.M. Muscarinic receptor subtypes in neuronal and nonneuronal cholinergic function. Auton. Autacoid Pharmacol., 2006, 26(3), 219-233. (Pubitemid 43898622)
23. Abrams, P.; Andersson, K.E.; Buccafusco, J.J.; Chapple, C.; de Groat, W.C.; Fryer, A.D.; Kay, G.; Laties, A.; Nathanson, N.M.; Pasricha, P.J.; Wein AJ. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br. J. Pharmacol., 2006, 148(5), 565-578. (Pubitemid 43993048)
24. Sabaawi, M.; Singh, N.N.; de Leon, J. Guidelines for the use of clozapine in individuals with developmental disabilities. Res. Dev. Disabil., 2006, 27(3), 309-336.
25. Ekström, J.; Godoy, T.; Riva, A. Clozapine: agonistic and antagonistic salivary secretory actions. J. Dent. Res., 2010, 89(3), 276-280.
26. Davies, M.A.; Compton-Toth, B.A.; Hufeisen, S.J.; Meltzer, H.Y.; Roth, B.L. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a prerequisite for mimicking clozapine's actions? Psychopharmacology, 2005, 178(4), 451-460. (Pubitemid 40486985)
27. Sur, C.; Mallorga, P.J.; Wittmann, M.; Jacobson, M.A.; Pascarella, D.; Williams, J.B.; Brandish, P.E.; Pettibone, D.J.; Scolnick, E.M.; Conn, P.J. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc. Natl. Acad. Sci. USA., 2003, 100(23), 13674-13679. (Pubitemid 37444798)
28. Flacker, J.M.; Cummings, V.; Mach, J.R. Jr; Bettin, K.; Kiely, D.K.; Wei, J. The association of serum anticholinergic activity with delirium in elderly medical patients. Am. J. Geriatr. Psychiatry, 1998, 6(1), 31-41. (Pubitemid 28051719)
29. Mintzer, J.; Burns, A. Anticholinergic side-effects of drugs in elderly people. J. R. Soc. Med., 2000, 93(9), 457-462.
30. Penttilä, J.; Scheinin, H.; Syvälahti, E. Measurement of anticholinergic effects of psychotropic drugs in humans. Pharmacopsychiatry, 2005, 38(5), 187-193. (Pubitemid 41414863)
31. Lacy, C.F.; Armstrong, L.L.; Goldman, M.P.; Lance, L.L. Drug Information Handbook, 18th ed.; Lexi-Comp, Inc.: Hudson, OH, 2009.
32. Oshika, T. Ocular adverse effects of neuropsychiatric agents. Incidence and management. Drug Saf., 1995, 12(4), 256-263.
33. Richelson, E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J. Clin. Psychiatry, 2003, 64(Suppl 13), 5-12. (Pubitemid 37267809)
34. Rekker, R.F.; Timmerman, H.; Harms, A.F.; Nauta, W.T. The antihistaminic and anticholinergic activities of optically active diphenhydramine derivatives: the concept of complementarity. Arzneimittelforschung, 1971, 21(5), 688-691.
35. Timmerman, H.; Rekker, R.F.; Harms, A.F.; Nauta, W.T. The effect of alkyl substitution in drugs. XXII. The antihistaminic and anticholinergic activity of a series of thio ether analogues of substituted diphenhydramines. Arzneimittelforschung, 1970, 20(9), 1258-1259.
36. Devillier, P.; Roche, N.; Faisy, C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin. Pharmacokinet., 2008, 47(4), 217-230. (Pubitemid 351367433)
37. Rudd, K.M.; Raehl, C.L.; Bond, C.A.; Abbruscato, T.J.; Stenhouse, A.C. Methods for assessing drug-related anticholinergic activity. Pharmacotherapy, 2005, 25(11), 1592-1601. (Pubitemid 41566918)
38. Coupet, J.; Fisher, S.K.; Rauh, C.E.; Lai, F.; Beer, B. Interaction of amoxapine with muscarinic cholinergic receptors: an in vitro assessment. Eur. J. Pharmacol., 1985, 112(2), 231-235. (Pubitemid 15038027)
39. Cusack, B.; Nelson, A.; Richelson, E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl)., 1994, 114(4), 559-565. (Pubitemid 24152135)
40. El-Fakahany, E.; Richelson, E. Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br. J. Pharmacol., 1983, 78(1), 97-102. (Pubitemid 13167583)
41. Golds, P.R.; Przyslo, F.R.; Strange, P.G. The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br. J. Pharmacol., 1980, 68(3), 541-549. (Pubitemid 10150998)
42. Nutt, D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr. Scand., 1997, 96(Suppl 391), 31-37.
43. Owens, M.J.; Morgan, W.N.; Plott, S.J.; Nemeroff, C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther., 1997, 283(3), 1305-1322. (Pubitemid 28016506)
44. Richelson, E.; Nelson, A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J. Pharmacol. Exp. Ther., 1984, 230(1), 94-102. (Pubitemid 14097664)
45. Snyder, S.H.; Yamamura, H.I. Antidepressants and the muscarinic acetylcholine receptor. Arch. Gen. Psychiatry, 1977, 34(2), 236-239. (Pubitemid 8025021)
46. Stanton, T.; Bolden-Watson, C.; Cusack, B.; Richelson, E. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem. Pharmacol., 1993, 45(11), 2352-2354. (Pubitemid 23171101)
47. Thomas, D.R.; Nelson, D.R.; Johnson, A.M. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl), 1987, 93(2), 193-200. (Pubitemid 18013056)
48. Tollefson, G.D.; Senogles, S.E.; Frey, W.H. 2nd. Ionic regulation of antagonist binding to the human muscarinic cholinergic receptor of caudate nucleus. J. Psychiatr. Res., 1982-1983, 17(3), 275-283. (Pubitemid 14242503)
49. Bymaster, F.P.; Falcone, J.F. Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium. Eur. J. Pharmacol., 2000, 390(3), 245-248. (Pubitemid 30119938)
50. Bymaster, F.P.; Hemrick-Luecke, S.K.; Perry, K.W.; Fuller, R.W. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl), 1996, 124(1-2), 87-94. (Pubitemid 26111437)
51. Bymaster, F.P.; Nelson, D.L.; DeLapp, N.W.; Falcone, J.F.; Eckols, K.; Truex, L.L.; Foreman, M.M.; Lucaites, V.L.; Calligaro, D.O. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr. Res., 1999, 37(1), 107-122. (Pubitemid 29167031)
52. Friedel, R.O.; Knauer, G. Actions of neuroleptics on the acetylcholine- induced phospholipid effect in rat neostriatal homogenates. Neuropharmacology, 1981, 20(10), 925-930. (Pubitemid 12199191)
53. Goldstein, J.M.; Brecher, M. Clarification of anticholinergic effects of quetiapine. J. Clin. Psychiatry, 2000, 61(9), 680.
54. Miller, R.J.; Hiley, C.R. Anti-dopaminergic and anti-muscarinic effects of dibenzodiazepines: relationship to drug induced Parkinsonism. Naunyn-Schmiedebergs Arch. Pharmacol., 1976, 292(3), 289-293.
55. Richelson, E.; Souder, T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci., 2000, 68(1), 29-39.
56. Saller, C.F.; Salama, A.I. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl.), 1993, 112(2-3), 285-292. (Pubitemid 23278291)
57. Snyder, S.; Greenberg, D.; Yamamura, H.I. Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch. Gen. Psychiatry, 1974, 31(1), 58-61.
58. Fjalland, B.; Christensen, A.V.; Hyttel, J. Peripheral and central muscarinic receptor affinity of psychotropic drugs. Naunyn-Schmiedebergs Arch. Pharmacol., 1977, 301(1), 5-9.
59. Richelson, E.; Divinetz-Romero, S. Blockade by psychotropic drugs of the muscarinic acetylcholine receptor in cultured nerve cells. Biol. Psychiatry, 1977, 12(6), 771-785. (Pubitemid 8255774)
60. Syvälahti, E.K.; Laurén, L.; Markkanen, J.; Kunelius, R. Interaction of psychotropic drugs with brain muscarinic cholinoceptors: similarities of biperiden with pirenzepine in receptor binding properties. Pharmacol. Toxicol., 1987, 60(1), 66-69. (Pubitemid 17042689)
61. Kubo, N.; Shirakawa, O.; Kuno, T.; Tanaka, C. Antimuscarinic effects of antihistamines: quantitative evaluation by receptorbinding assay. Jpn. J. Pharmacol., 1987, 43(3), 277-282. (Pubitemid 17034958)
62. Hegde, S.S. Muscarinic receptors in the bladder: from basic research to therapeutics. Br. J. Pharmacol., 2006, 147(Suppl 2), S80-S87. (Pubitemid 43237576)
63. Richelson, E. Receptor pharmacology of neuroleptics: Relation to clinical effects. J. Clin. Psychiatry, 1999, 60(Suppl 10), 5-14. (Pubitemid 29237170)
64. Lavalaye, J.; Booij, J.; Linszen, D.H.; Reneman, L.; van Royen, E.A. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. Psychopharmacology (Berl), 2000, 156(1), 53-57.
65. Raedler, T.J.; Knable, M.B.; Jones, D.W.; Lafargue, T.; Urbina, R.A.; Egan, M.F.; Pickar, D.; Weinberger, D.R. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology, 2000, 23(1), 56-68. (Pubitemid 30408312)
66. Raedler, T.J.; Knable, M.B.; Jones, D.W.; Urbina, R.A; Egan, M.F.; Weinberger, D.R. Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology, 2003, 28(8), 1531-1537. (Pubitemid 41070889)
67. Dazzi, L.; Vacca, G.; Ladu, S.; Pisu, M.G.; Serra, M.; Biggio, G. Long-term treatment with antidepressant drugs reduces the sensitivity of cortical cholinergic neurons to the activating actions of stress and the anxiogenic drug FG 7142. Neuropharmacology, 2001, 41(2), 229-237. (Pubitemid 32728094)
68. Dilsaver, S.C.; Davidson, R. Cholinergic properties of desipramine and amoxapine: assessment using a thermoregulation paradigm. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1987, 11(5), 581-599. (Pubitemid 18015853)
69. Fujishiro, J.; Imanishi, T.; Onozawa, K.; Tsushima, M. Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. Eur. J. Pharmacol., 2002, 454(2-3), 183-188. (Pubitemid 35287477)
70. Tune, L.; Coyle, J.T. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch. Gen. Psychiatry, 1980, 37(3), 293-297. (Pubitemid 10102554)
71. de Leon, J.; Odom-White, A.; Josiassen, R.C.; Diaz, F.J.; Cooper, T.B.; Simpson, G.M. Serum muscarinic activity during clozapine treatment. J. Clin. Psychopharmacol., 2003, 23(4), 336-341. (Pubitemid 36951174)
72. Flacker, J.M.; Wei, J.Y. Endogenous anticholinergic substances may exist during acute illness in elderly medical patients. J. Gerontol. A. Biol. Sci. Med. Sci., 2001, 56(6), M353-M355. (Pubitemid 32522253)
73. Carnahan, R.M.; Lund, B.C.; Perry, P.J.; Pollock, B.G. A critical appraisal of the utility of the serum anticholinergic activity assay in research and clinical practice. Psychopharmacol. Bull., 2002, 36(2), 24-39.
74. Minzenberg, M.J.; Poole, J.H.; Benton, C.; Vinogradov, S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatry, 2004, 161(1), 116-124. (Pubitemid 38419316)
75. Vinogradov, S.; Fisher, M.; Warm, H.; Holland, C.; Kirshner, M.A.; Pollock, B.G. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am. J. Psychiatry, 2009, 166(9), 1055-1062.
76. Carnahan, R.M.; Lund, B.C.; Perry, P.J.; Culp, K.R.; Pollock, B.G. The relationship of an anticholinergic rating scale with serum anti cholinergic activity in elderly nursing home residents. Psychopharmacol. Bull., 2002, 36(4), 14-19.
77. Tune, L.E.; Egeli, S. Acetylcholine and delirium. Dement. Geriatr. Cogn. Disord., 1999, 10(5), 342-344. (Pubitemid 29403592)
78. Chew, M.L.; Mulsant, B.H.; Pollock, B.G.; Pollock, B.G.; Lehman, M.E.; Greenspan, A.; Kirshner, M.A.; Bies, R.R.; Kapur, S.; Gharabawi, G. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr. Res., 2006, 88(1-3), 63-72. (Pubitemid 44693242)
79. Holm, K.J.; Markham, A. Mirtazapine: a review of its use in major depression. Drugs, 1999, 57(4), 607-631. (Pubitemid 29196924)
80. Kantrowitz, J.T.; Citrome, L. Olanzapine: review of safety. Expert. Opin. Drug Saf., 2008, 7(6), 761-769.
81. Kennedy, J.S.; Zagar, A.; Bymaster, F.; Nomikos, G.; Trzepacz, P.T.; Gilmore, J.A.; Rotelli, M.D.; Breier, A.; Tollefson, G. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. Int. J. Geriatr. Psychiatry, 2001, 16(Suppl 1), S24-S32. (Pubitemid 33741566)
82. Montgomery, S.A. Safety of mirtazapine: a review. Int. Clin. Psychopharmacol., 1995, 10(Suppl 4), 37-45. (Pubitemid 26058318)
83. Smith, W.T.; Glaudin, V.; Panagides, J.; Gilvary, E. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol. Bull., 1990, 26(2), 191-196. (Pubitemid 20291874)
84. Arima, Y.; Kubo, C.; Tsujimoto, M.; Ohtani, H.; Sawada, Y. Improvement of dry mouth by replacing paroxetine with fluvoxamine. Ann. Pharmacother., 2005, 39(3), 567-571. (Pubitemid 40270929)
85. Cohen, R.; Wilkins, K.M.; Ostroff, R.; Tampi, R.R. Olanzapine and acute urinary retention in two geriatric patients. Am. J. Geriatr. Pharmacother., 2007, 5(3), 241-246. (Pubitemid 350063663)
86. Raedler, T.J.; Reimer, J.; Wiedemann, K. Dose-dependent constipation with higher doses of quetiapine: a case series. Int. Clin. Psychopharmacol., 2007, 22(4), 244-246. (Pubitemid 46801949)
87. Sokolski, K.N.; Brown, B.J.; Melden, M. Urinary retention following repeated high-dose quetiapine. Ann. Pharmacother., 2004, 38(5), 899-900. (Pubitemid 38509076)
88. Tsao, J.W.; Heilman, K.M. Transient memory impairment and hallucinations associated with tolterodine use. N. Engl. J. Med., 2003, 349(23), 2274-2275. (Pubitemid 37485153)
89. Womack, K.B.; Heilman, K.M. Tolterodine and memory: dry but forgetful. Arch. Neurol., 2003, 60(5), 771-773. (Pubitemid 36569899)
90. Garver, D.L. Review of Quetiapine Side Effects. J. Clin. Psychiatry, 2000, 61(Suppl 8), 31-33.
91. Gunasekara, N.S.; Spencer, C.M. Quetiapine a review of its use in schozophrenia. CNS Drugs, 1998, 9(4), 325-340. (Pubitemid 28210367)
92. Kasper, S.; Müller-Spahn, F. Review of quetiapine and its clinical applications in schizophrenia. Exp. Opin. Pharmacother., 2000, 1(4), 783-801.
93. Nasrallah, H.A.; Tandon, R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J. Clin. Psychiatry, 2002, 63(Suppl 13), 12-20. (Pubitemid 35471365)
94. Tariot, P.N.; Ismail, M.S. Use of quetiapine in elderly patients. J. Clin. Psychiatry, 2002, 63(Suppl 13), 21-26. (Pubitemid 35471366)
95. Astra Zeneca. Seroquel (Quetiapine Fumarate Tablets) Package Insert, Astra Zeneca: Wilmington, DE, 2010.
96. Altman, D.; Machin, D.; Bryant, T.; Gardner, S. Statistics with Confidence: Confidence Intervals and Statistical Guidelines 2nd ed.; BMJ Books: Bristol, 2000.
97. Citrome, L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr. Drug Saf., 2009, 4(3), 229-237.
98. Arnold, S.E.; Kahn, R.J.; Faldetta, L.L.; Laing, R.A.; McNair, D.M. Tricyclic antidepressants and peripheral anticholinergic activity. Psychopharmacology (Berl), 1981, 74(4), 325-328. (Pubitemid 11003750)
99. Blackwell, B.; Stefopoulos, A.; Enders, P.; Kuzma, R.; Adolphe, A. Anticholinergic activity of two tricyclic antidepressants. Am. J. Psychiatry, 1978, 135(6), 722-724. (Pubitemid 8344612)
100. Breuel, H.P.; Mürtz, G.; Bondy, S.; Horkulak, J.; Gianetti, B.M. Safety and tolerance of trospium chloride in the high dose range. Arzneimittelforschung, 1993, 43(4), 461-464. (Pubitemid 23112986)
101. Carlini, E.L.; Del-Porto, J.A.; Zwicker, A.P.; Braz, J. Lack of agreement between the salivary flow and finger-sweat print methods for the determination of the anticholinergic effects of antidepressant drugs. Braz. J. Med. Biol. Res., 1985, 18(2), 163-169. (Pubitemid 15062002)
102. Peterson, G.R.; Blackwell, B.; Hostetler, R.M.; Kuzma, R.; Adolphe, A. Anticholinergic activity of the tricyclic antidepressants desipramine and doxepin in nondepressed volunteers. Commun. Psychopharmacol., 1978, 2(2), 145-150. (Pubitemid 9067294)
103. Szabadi, E.; Gaszner, P.; Bradshaw, C.M. The peripheral anticholinergic activity of tricyclic antidepressants: comparison of amitriptyline and desipramine in human volunteers. Br. J. Psychiatry, 1980, 137, 433-439. (Pubitemid 10030107)
104. Blazer, D.G. 2nd; Federspiel, C.F.; Ray, W.A.; Schaffner, W. The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations. J. Gerontol., 1983, 38(1), 31-35. (Pubitemid 13217827)
105. Landi, F.; Russo, A.; Liperoti, R.; Cesari, M.; Barillaro, C.; Pahor, M.; Bernabei, R.; Onder, G. Anticholinergic drugs and physical function among frail elderly population. Clin. Pharmacol. Ther., 2007, 81(2), 235-241. (Pubitemid 46174821)
106. Lechevallier-Michel, N.; Molimard, M.; Dartigues, J.F.; Fabrigoule, C.; Fourrier-Réglat, A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Br. J. Clin. Pharmacol., 2005, 59(2), 143-151. (Pubitemid 40208849)
107. Summers, W.R. A clinical method of estimating risk factors of drug-induced delirium. Life Sci., 1978, 22(17), 1511-1516.
108. Menkes, D.B.; Clarkson, H.O.; Caradoc-Davies, G.; Mullen, P.E. Anticholinergic equivalents and parkinsonism: a model for predicting side-effects of antipsychotic drugs. Int. Clin. Psychopharmacol., 1987, 2(1), 55-67.
109. de Leon, J.; Canuso, C.; White, A.O.; Simpson, G.M. A pilot effort to determine benztropine equivalents of anticholinergic medications. Hosp. Community Psychiatry, 1994, 45(6), 606-607. (Pubitemid 24162027)
110. Han, L.; McCusker, J.; Cole, M.; Abrahamowicz, M.; Primeau, F.; Elie, M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch. Intern. Med., 2001, 161(8), 1099-1105. (Pubitemid 32685536)
111. Carnahan, R.M.; Lund, B.C.; Perry, P.J.; Pollock, B.G.; Culp, K.R. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J. Clin. Pharmacol., 2006, 46(12), 1481-1486. (Pubitemid 44704208)
112. Rudolph, J.L.; Salow, M.J.; Angelini, M.C.; McGlinchey, R.E. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch. Intern. Med., 2008, 168(5), 508-513. (Pubitemid 351547214)
113. Ancelin, M.L.; Artero, S.; Portet, F.; Dupuy, A.M.; Touchon, J.; Ritchie, K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. Br. Med. J., 2006, 332(7539), 455-459.
114. de Leon, J. Benztropine equivalents for antimuscarinic medication (letter). Am. J. Psychiatry, 2005, 162(3), 627. (Pubitemid 40343941)
115. Weinberger, D.R.; Gibson, R.; Coppola, R.; Jones, D.W.; Molchan, S.; Sunderland, T.; Berman, K.F.; Reba, R.C. The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia. A controlled study with 123IQNB and single photon emission computed tomography. Arch. Neurol., 1991, 48(2), 169-176.
116. Sunderland, T.; Tariot, P.N.; Cohen, R.M.; Weingartner, H.; Mueller, E.A. 3rd; Murphy, D.L. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch. Gen. Psychiatry, 1987, 44(5), 418-426. (Pubitemid 17064486)
117. Kirstein, S.L.; Insel, P.A. Autonomic nervous system pharmacogenomics: a progress report. Pharmacol. Rev., 2004, 56(1), 31-52. (Pubitemid 38314579)
118. Turnheim, K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp. Gerontol., 2003, 38(8), 843-853. (Pubitemid 36952666)
119. Hoffman, B.B. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed.; L. L. Brunton; J. S. Lazo; K. L. Parker, Eds.; McGraw-Hill: New York, 2006; pp. 845-868.
120. Arce, D.A.; Ermocilla, C.A.; Costa, H. Evaluation of constipation. Am. Fam. Physician, 2002, 65(11), 2283-2290.
121. Bouras, E.P.; Tangalos, E.G. Chronic constipation in the elderly. Gastroenterol. Clin. North Am., 2009, 38(3), 463-480.
122. Jacobs, T.Q.; Pamies, R.J. Adult constipation: a review and clinical guide. J. Natl. Med. Assoc., 2001, 93(1), 22-30. (Pubitemid 33603520)
123. Spinzi, G.C. Bowel care in the elderly. Dig. Dis., 2007, 25(2), 160-165. (Pubitemid 46663783)
124. Martin-Latry, K.; Goumy, M.P.; Latry, P.; Gabinski, C.; Bégaud, B.; Faure, I.; Verdoux, H. Psychotropic drugs use and risk of heatrelated hospitalisation. Eur. Psychiatry, 2007, 22(6), 335-338. (Pubitemid 47391219)
125. Stadnyk, A.N.; Glezos, J.D. Drug-induced heat stroke. Can. Med. Assoc. J., 1983, 128(8), 957-959. (Pubitemid 13088717)
126. Turnheim, K. Pharmacokinetic dosage guidelines for elderly subjects. Expert Opin. Drug Metab. Toxicol., 2005, 1(1), 33-48.
127. Kinirons, M.T.; O'Mahony, M.S. Drug metabolism and ageing. Br. J. Clin. Pharmacol., 2004, 57(5), 540-544. (Pubitemid 38582172)
128. Schwartz, J.B. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin. Pharmacol. Ther., 2007, 82(1), 87-96. (Pubitemid 46944201)
129. Dahl, M.L. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: Useful aid to prescribing. Clin. Pharmacokinet., 2002, 41(7), 453-470.
130. de Leon, J.; Armstrong, S.C.; Cozza, K.L. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics, 2006, 47(1), 75-85. (Pubitemid 43017126)
131. Kirchheiner, J.; Nickchen, K.; Bauer, M.; Wong, M.L.; Licinio, J.; Roots, I.; Brockmoller, J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry, 2004, 9(5), 442-473. (Pubitemid 38903502)
132. Scordo, M.G.; Spina, E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics, 2002, 3(2), 201-218. (Pubitemid 34223857)
133. Zhou, S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin. Pharmacokinet., 2009, 48(12), 761-804.
134. Armstrong, S.C.; Schweitzer, S.M. Delirium associated with paroxetine and benztropine combination (letter). Am. J. Psychiatry, 1997, 154(4), 581-582. (Pubitemid 27147623)
135. de Leon, J.; Nikoloff, D.M. Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports. CNS Spectrums, 2008, 13(2), 133-135.
136. Spina, E.; Santoro, V.; D'Arrigo, C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin. Ther., 2008, 30(7), 1206-1227.
137. de Leon, J.; Armstrong, S.C.; Cozza, K.L. The dosing of atypical antipsychotics. Psychosomatics, 2005, 46(3), 262-273. (Pubitemid 40594318)
138. Spina, E.; de Leon, J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin. Pharmacol. Toxicol., 2007, 100(1), 4-22. (Pubitemid 46051438)
139. Diaz, F.J.; Santoro, V.; Spina, E.; Cogollo, M.; Rivera, T.E.; Botts, S.; de Leon, J. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry, 2008, 41(3), 81-91. (Pubitemid 351796981)
140. Brosen, K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie, 2004, 59(1), 5-12. (Pubitemid 38765554)
141. de Leon, J.; Susce, M.T.; Johnson, M.; Hardin, M.; Maw, L.; Shao, A., Allen, A.C.; Chiafari, F.A.; Hillman, G.; Nikoloff, D,M. DNA microarray technology in the clinical environment: The AmpliChip CYP 450 Test for CYP2D6 and CYP2C19 genotyping. CNS Spectrums, 2009, 14(1), 19-34.
142. Howe, E. Initial screening of patients for Alzheimer's disease and minimal cognitive impairment. Psychiatry (Edgmont), 2007, 4(7), 24-27.